Who owns Lakefront Biotherapeutics NV (GLPG)? Elite investor 13F holders

3 tracked elite investors reported holding Lakefront Biotherapeutics NV as of 2026-09-30, including Greenlight Capital, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Greenlight CapitalGALAPAGOS NVSHARE2026-09-302026-11-16 00:00:0014313419.00 USD482746.000000SharesholdOriginal filing
Renaissance Technologies LLCGALAPAGOS NVSHARE2026-09-302026-11-12 00:00:0012592355.00 USD424700.000000SharesaddOriginal filing
D.E. ShawGALAPAGOS NVSHARE2026-09-302026-11-16 00:00:009655819.00 USD325660.000000SharesaddOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown